Oral Answers to Questions

Debate between Mark Menzies and Paul Scully

Wednesday 3rd May 2023 Commons Chamber

[Mark Menzies (Fylde) (Con)]

10. What steps her Department is taking to support the international competitiveness of the science and technology sector.

[The Parliamentary Under-Secretary of State for Science, Innovation and Technology (Paul Scully)]

The Government published the science and technology framework in March 2023, setting out our approach to making the UK a science and technology superpower by 2030. This will increase the UK’s strategic advantage in relation to other nations. As part of that, we have a 10-point plan, having identified five critical technologies, including AI, semiconductors and quantum, which we will prioritise to deliver the framework’s ambition.

[Paul Scully]

I acknowledge my hon. Friend’s work to encourage innovation, including at Syngenta. My colleague, the Minister for Science, Research and Innovation, has already met Syngenta, and one of us will follow up with my hon. Friend to see what more we can do to support innovation in the Bracknell area.

[Mark Menzies]

We have a truly world-class nuclear skillset in Fylde, with Springfields being home to the country’s only nuclear fuel-manufacturing facility and the National Nuclear Laboratory, which last year made a significant breakthrough in developing lead-212, a cancer-fighting medical isotope. There are real opportunities not only to preserve but to build on that success. What conversations has my hon. Friend had with the Prime Minister and other Ministers about ensuring our domestic nuclear capability is the go-to choice for use in the UK and about maximising opportunities abroad?

[Paul Scully]

My hon. Friend always champions industry and innovation in his area. We recognise the UK’s significant capabilities in the nuclear fuel cycle and the benefit this provides to our energy security and to realising export opportunities. Through the nuclear fuel fund, the Government are investing in Springfields and other parts of the supply chain to further expand essential capabilities so we can realise benefits for the UK and abroad. The £6 million medical radionuclide innovation programme will also develop capability in the production of radionuclides for medicine.